The stock has now fallen nearly 30% since the end of March.
News & Analysis: United Therapeutics
UTHR earnings call for the period ending March 31, 2019.
UTHR earnings call for the period ending December 31, 2018.
The company moved to immediately monetize a promising drug candidate. For a cool $800 million up-front payment, investors can't complain.
UTHR earnings call for the period ending September 30, 2018.
A new collaboration is funneling tens of millions of dollars onto the diabetes company’s balance sheet.
Shares soar for the second day in a row. What can explain the bullish move?
Shares are soaring following the company's announcement of a new partnership agreement. Here's what investors need to know.
These stocks are definitely inexpensive. But are they buys?
These stocks led the way higher. Find out why.